GEXVal CTO to Present at the Annual Meeting of the PSJ

GEXVal Inc.
March 25, 2026

GEXVal CTO to Present at the 146th Annual Meeting of the Pharmaceutical Society of Japan

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Chief Technology Officer Dr. Yusuke Nakayama will present a poster at the 146th Annual Meeting of the Pharmaceutical Society of Japan.

[Event Overview]
This poster presentation will introduce a data-driven approach to rare disease indication exploration that integrates Graph Neural Networks (GNNs) and large language models (LLMs). The research features knowledge graph analysis via Graph Attention Autoencoder (GATE)¹⁾, combined with LLMs connected to external databases and patent information through Model Context Protocol (MCP) and Retrieval-Augmented Generation (RAG). This multi-layered system enables AI agent-driven, multidimensional evaluation of target-disease compatibility and feasibility. Through this approach, GEXVal aims to identify new rare disease indication candidates for existing drugs, contributing to the acceleration and precision improvement of the drug discovery process.

**Presentation Details**

1) About Graph Attention Autoencoder（GATE）
Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods.

[About the Pharmaceutical Society of Japan]
The Pharmaceutical Society of Japan (PSJ) is an academic organization with over 140 years of history, hosting one of Japan's leading scientific conferences that brings together experts across a broad spectrum of fields — from basic and clinical pharmacy to drug discovery science. In recent years, next-generation technologies such as AI-driven drug discovery and real-world data utilization have become prominent themes, and the annual meeting serves as a key platform for industry-academia-government collaboration, driving innovation to address advanced medical needs.

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com